When will you recommend enfortumab vedotin plus pembrolizumab as first-line treatment of metastatic urothelial carcinoma for cisplatin-ineligible patients?  

This is a timely question given the US FDA approval of the pembro/EV combination on 4/3/2023. Currently, the label is for patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy. There are a variety of definitions for cisplatin ineli...

The enfortumab vedotin (EV) + pembrolizumab regimen received accelerated approval by the US FDA in April 2023 for cisplatin-ineligible patients with advanced urothelial carcinoma. The approval was based on cohorts A (Phase I/Ib) and K (randomized phase II comparison of EV vs. EV+pembrolizumab) of th...